FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Cyclin-dependent kinase 4 (CDK4) and retinoblastoma protein (RB) are key regulators of the cell cycle.
• Dysregulation of cell-cycle control is a hallmark of cancer, particularly colorectal cancer (CRC).
• Understanding novel regulators of CDK4/RB pathway is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the role of FERM domain-containing 8 (FRMD8) in regulating cell-cycle progression and colorectal cancer growth.
• To elucidate the molecular mechanisms by which FRMD8 affects CDK4 activation and RB stability.
• To explore the therapeutic potential of FRMD8 or its derivatives in colorectal cancer treatment.

Main Methods:

• Co-immunoprecipitation assays to study protein-protein interactions (FRMD8, CDK4, CDK7, MDM2, RB).
• Cell-cycle analysis and proliferation assays in CRC cell lines.
• In vivo studies using a mouse model of colorectal adenoma formation.
• Analysis of FRMD8 promoter methylation and correlation with patient prognosis.

Main Results:

• FRMD8 inhibits CDK4 activation by disrupting the CDK7-CDK4 interaction.
• FRMD8 stabilizes RB by competing with MDM2, thereby preventing RB degradation.
• Frmd8 deficiency accelerated colorectal adenoma formation in mice.
• Hypermethylation of the FRMD8 promoter and low FRMD8 expression correlate with poor CRC prognosis.
• An FRMD8-derived peptide (LKCHE-containing) stabilized RB and, when combined with a CDK4 inhibitor, suppressed CRC cell growth.

Conclusions:

• FRMD8 acts as a tumor suppressor in colorectal cancer by inhibiting CDK4 activation and stabilizing RB.
• FRMD8 expression is epigenetically silenced in CRC, and its downregulation predicts poor patient outcomes.
• Targeting the MDM2-RB interaction with FRMD8-derived peptides represents a promising therapeutic strategy for CDK4/6 inhibitor-resistant colorectal cancer.